Evidence map›Paper›PMID 20930072›Full record

ReviewClinical microbiology reviews2010

Infections of people with complement deficiencies and patients who have undergone splenectomy.

Sanjay Ram, Lisa A Lewis, Peter A Rice

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04295733 (Evaluation of Safety, Tolerability and Immunogenicity of Two Doses of the 4CMenB Vaccine in Adults With an Immunodeficiency), which is not on this map. Cited by 178 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed, 2 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04295733 completednot on this mapstarted 2020, after this paper: background citation

Evaluation of Safety, Tolerability and Immunogenicity of Two Doses of the 4CMenB Vaccine in Adults With an Immunodeficiency

TypeobservationalSponsorOspedale Policlinico San MartinoRan2020 to 2024Enrolled98ConditionsAcquired ImmunodeficiencyArms4CMenB (Bexsero®) vaccine
3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 2 syntheses or guidelines pooled it, 391 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Innate immunity: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review
  5. Article
  6. Universal-BacMicrobiologyOpen · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Frontiers in microbiology · 2026
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sanjay RamDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Lazare Research Building, Room 322, 364 Plantation Street, Worcester, MA 01605, USA. sanjay.ram@umassmed.edu
Lisa A Lewis
Peter A Rice
University of Massachusetts Chan Medical School · US

Funding

The TLR4/MD-2 signaling pathway in gonoccocal diseaseU19AI084048 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI REED, GEORGE W. · 2009 to 2013
$13.1M
Immunology of Infection with Neisseria gonorrhoeaeR37AI032725 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RICE, PETER A. · 2004 to 2013
$6.1M
Complement Activation on Neisseria meningitidisR01AI054544 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY · 2004 to 2014
$3.4M
IMMUNOLOGY OF INFECTION WITH NEISSERIA GONORRHOEAER01AI032725 · NIAID · BOSTON MEDICAL CENTER · PI RICE, PETER A. · 1993 to 2003
$1.8M
Immunology of Infection with Neisseria gonorrhoeaeR56AI032725 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2014 to 2014
$583k
NIAID NIH HHS AI054544NIAID NIH HHS AI084048NIAID NIH HHS AI32725NIAID NIH HHS R01 AI032725NIAID NIH HHS R01 AI054544NIAID NIH HHS R37 AI032725NIAID NIH HHS R56 AI032725NIAID NIH HHS U19 AI084048
6 · The paper itself

Abstract

The complement system comprises several fluid-phase and membrane-associated proteins. Under physiological conditions, activation of the fluid-phase components of complement is maintained under tight control and complement activation occurs primarily on surfaces recognized as "nonself" in an attempt to minimize damage to bystander host cells. Membrane complement components act to limit complement activation on host cells or to facilitate uptake of antigens or microbes "tagged" with complement fragments. While this review focuses on the role of complement in infectious diseases, work over the past couple of decades has defined several important functions of complement distinct from that of combating infections. Activation of complement in the fluid phase can occur through the classical, lectin, or alternative pathway. Deficiencies of components of the classical pathway lead to the development of autoimmune disorders and predispose individuals to recurrent respiratory infections and infections caused by encapsulated organisms, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. While no individual with complete mannan-binding lectin (MBL) deficiency has been identified, low MBL levels have been linked to predisposition to, or severity of, several diseases. It appears that MBL may play an important role in children, who have a relatively immature adaptive immune response. C3 is the point at which all complement pathways converge, and complete deficiency of C3 invariably leads to severe infections, including those caused by meningococci and pneumococci. Deficiencies of the alternative and terminal complement pathways result in an almost exclusive predisposition to invasive meningococcal disease. The spleen plays an important role in antigen processing and the production of antibodies. Splenic macrophages are critical in clearing opsonized encapsulated bacteria (such as pneumococci, meningococci, and Escherichia coli) and intraerythrocytic parasites such as those causing malaria and babesiosis, which explains the fulminant nature of these infections in persons with anatomic or functional asplenia. Paramount to the management of patients with complement deficiencies and asplenia is educating patients about their predisposition to infection and the importance of preventive immunizations and seeking prompt medical attention.

Indexed as

SplenectomyAnimalsAutoimmune DiseasesChildChild, PreschoolComplement ActivationComplement System ProteinsFemaleHaemophilus influenzaeHumansImmunologic Deficiency SyndromesMaleMeningococcal InfectionsNeisseria meningitidisRespiratory Tract InfectionsStreptococcus pneumoniaeComplement System Proteins

Identifiers

PMID20930072
PMCPMC2952982
OpenAlexW2112430000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.